REC-1245 — Interim data
2H26
• REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26Source filing
RXRX biotech catalysts & pipeline
RECURSION PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
REC-4881 — FDA meeting
2H26
• Discussions with FDA were initiated in 1H26 and an update to define the registrational path is expected in 2H26Source filing
REC-4881 — Regulatory decision
2H26
Regulatory update expected in 2H26Source filing
REC-3565 — Interim data
1H27
Early Phase 1 safety and PK monotherapy data expected in 1H27Source filing
REC-4881 — Topline data
1H27
Additional Phase 1b/2 clinical data expected in 1H27Source filing
REC-617 — Interim data
1H27
Early Phase 1 safety and PK combination data expected in 1H27Source filing
REC-4539 — Interim data
2H27
Early Phase 1 safety and PK monotherapy data expected in 2H27Source filing
REC-4881 — Conference presentation
Nov 2
◦ Session date and time: Monday November 2, 2026; 13:30 - 15:00 MSTSource filing